Financial comparisons Monte Rosa Therapeutics, Inc.
Stocks
GLUE
US61225M1027
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.56 USD | +6.04% |
|
+6.60% | +56.63% |
| 06-29 | Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2500 Growth Benchmark | CI |
| 06-29 | Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell Microcap Value Benchmark Index | CI |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
 | 124M | -31.23% | -43.83% | -16.94% | -8.71% | - | |
| 5.34B | 5.37% | 8.37% | 29.84% | 16.27% | -5.99x | |
| 16.31B | 8.34% | 13.38% | 32.9% | 4.79% | 3.63x | |
| 2.88B | 24.74% | 28.07% | 5.94% | 4.75% | 1.77x | |
| 846M | -31.67% | -18.92% | - | - | 1.57x | |
| 2.53B | 17.83% | 20.93% | 70.23% | 22.13% | -0.89x | |
| 8.57B | 6.51% | 14.79% | 9.61% | 4.34% | 2.22x | |
| 8.25B | 2.78% | 16.66% | 10.62% | 6.02% | 1.8x | |
| 5.4M | -7,306.52% | -5,350% | -135.58% | - | 2.1x | |
| 1.22B | 6.02% | 31.45% | 15.37% | 11.65% | 0.43x | |
| 4.02B | -3.59% | 19.77% | 15.46% | 6.99% | 1.98x | |
| 1.27B | -19.27% | -3.71% | -38.64% | -6.61% | -65.61x | |
| 2.02B | 11.8% | 13.68% | 11.6% | 6.52% | 1.83x | |
| 39.21M | -794.04% | -891.07% | -25.78% | -22.89% | 4.75x | |
| 944M | -40.36% | -40.47% | -70.72% | -11.67% | 4.51x | |
| 1.48B | 16.37% | 17.21% | 14.72% | 10.64% | -2.06x | |
| 2.09B | 20.33% | 29.46% | 17.5% | 10.73% | 0.74x | |
| Average | 3.41B | -476.86% | -360.84% | -3.37% | 3.66% | -2.95x | |
| Weighted average by Cap. | 5.03B | -378.3% | -281.23% | 6.68% | 6.38% | -1.84x |
- Stock Market
- Stocks
- GLUE Stock
- Sector Monte Rosa Therapeutics, Inc.
- Financial comparisons
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
